KR102601551B1 - Composition for skin improvement containing liriopesides B - Google Patents
Composition for skin improvement containing liriopesides B Download PDFInfo
- Publication number
- KR102601551B1 KR102601551B1 KR1020160083708A KR20160083708A KR102601551B1 KR 102601551 B1 KR102601551 B1 KR 102601551B1 KR 1020160083708 A KR1020160083708 A KR 1020160083708A KR 20160083708 A KR20160083708 A KR 20160083708A KR 102601551 B1 KR102601551 B1 KR 102601551B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- formula
- cosmetic composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 230000006872 improvement Effects 0.000 title abstract description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title description 6
- 230000000694 effects Effects 0.000 claims abstract description 69
- 230000037303 wrinkles Effects 0.000 claims abstract description 38
- 239000002537 cosmetic Substances 0.000 claims abstract description 32
- 230000002087 whitening effect Effects 0.000 claims abstract description 31
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010035532 Collagen Proteins 0.000 claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 27
- 229920001436 collagen Polymers 0.000 claims abstract description 27
- 230000037394 skin elasticity Effects 0.000 claims abstract description 25
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 23
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 22
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 102000029816 Collagenase Human genes 0.000 claims abstract description 18
- 108060005980 Collagenase Proteins 0.000 claims abstract description 18
- 229960002424 collagenase Drugs 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 27
- 239000004480 active ingredient Substances 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 2
- 239000013040 bath agent Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 26
- 239000000126 substance Substances 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000013641 positive control Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229930003268 Vitamin C Natural products 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 235000013376 functional food Nutrition 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 235000019154 vitamin C Nutrition 0.000 description 11
- 239000011718 vitamin C Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000016942 Elastin Human genes 0.000 description 8
- 108010014258 Elastin Proteins 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 229920002549 elastin Polymers 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- -1 tracant Substances 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 6
- 230000007760 free radical scavenging Effects 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 229960000271 arbutin Drugs 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108060003393 Granulin Proteins 0.000 description 3
- 241001448331 Liriope spicata Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KSIVGTKSVYIZEB-GDUJLLAZSA-N Ophiopogonin A Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](OC(C)=O)[C@H]1O KSIVGTKSVYIZEB-GDUJLLAZSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical group 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZLFQNOJSYZSINX-PVJKAEHXSA-N (2s)-2-[[(2s)-1-[2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C(=O)\C=C\C1=CC=CO1 ZLFQNOJSYZSINX-PVJKAEHXSA-N 0.000 description 1
- YMMPZCZOLKBHAP-IHPCNDPISA-N (2s)-2-[[(2s)-1-[2-[[2-[[(2s)-1-[2-(phenylmethoxycarbonylamino)acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)[C@H]1N(C(=O)CNC(=O)OCC=2C=CC=CC=2)CCC1 YMMPZCZOLKBHAP-IHPCNDPISA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241001532026 Liriope muscari Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 릴리오페사이드 비(liriopeseides B)를 포함하는 화장료 조성물에 관한 것으로, 보다 상세하게는 피부 미백, 피부 탄력 증진, 주름 개선 또는 보습 등의 우수한 효과를 가지는 화장료 조성물에 관한 것이다. 본 발명의 조성물은 저농도에서도 뛰어난 멜라닌 총량 감소 효과를 나타내고 콜라겐 합성 촉진 효과, 엘라스타제 및 콜라게네이즈 활성 저해 효과가 우수하며, 항당화 및 항산화 효과가 우수하여 피부 미백용, 탄력 증진용 또는 주름 개선용, 및 피부 보습용 화장료 조성물로서 사용할 수 있다. 또한, 본 발명의 릴리오페사이드 비를 포함하는 조성물은 식품 조성물 및 의약외품 조성물로서 사용할 수 있다.The present invention relates to a cosmetic composition containing liriopeseides B, and more specifically, to a cosmetic composition that has excellent effects such as skin whitening, skin elasticity improvement, wrinkle improvement, or moisturizing. The composition of the present invention has an excellent effect of reducing the total amount of melanin even at low concentrations, has an excellent effect of promoting collagen synthesis, inhibiting elastase and collagenase activity, and has excellent anti-glycation and antioxidant effects for skin whitening, improving elasticity, or wrinkles. It can be used as a cosmetic composition for improving and moisturizing the skin. Additionally, the composition containing Liliopeside ratio of the present invention can be used as a food composition and quasi-drug composition.
Description
본 발명은 릴리오페사이드 비(liriopeseides B)를 포함하는 화장료 조성물에 관한 것으로서, 보다 상세하게는 피부 미백, 피부 탄력 증진, 주름 개선 또는 보습 등의 우수한 효과를 가지는 화장료 조성물에 관한 것이다. 또한, 본 발명은 릴리오페사이드 비를 포함하는 식품 조성물 및 의약외품 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing liriopeseides B, and more specifically, to a cosmetic composition that has excellent effects such as skin whitening, skin elasticity improvement, wrinkle improvement, or moisturizing. Additionally, the present invention relates to food compositions and quasi-drug compositions containing liliopeside ratio.
일반적으로 알려진 미백 성분으로서, 코지산(Kojic acid) 또는 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민 C(L-Ascorbic acid) 또는 이들의 유도체와 각종 식물 추출물이 있다. 이들은 멜라닌 색소의 합성을 저해함으로써, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착증의 개선이 가능하다. 그러나 피부 적용 시, 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적인 효과를 기대할 수 없는 문제점이 있다.Commonly known whitening ingredients include substances that inhibit tyrosinase enzyme activity such as kojic acid or arbutin, hydroquinone, vitamin C (L-Ascorbic acid) or their derivatives, and various plant extracts. There is. By inhibiting the synthesis of melanin pigment, they can not only brighten skin tone and achieve skin whitening, but also improve skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, or genetics. However, when applied to the skin, there is a limit to the amount of use due to safety issues such as irritation and redness, or the effect is so small that no practical effect can be expected.
콜라겐은 피부의 섬유아세포(Fibroblast)에서 생성되는 주요 기질 단백질로서 세포 외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포 분할과 분화(유기체의 성장 혹은 상처 치유 시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 콜라겐을 분해하는 콜라게나제 효소 활성으로 콜라겐 감소가 촉진된다. 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다.Collagen is a major matrix protein produced by skin fibroblasts and is present in the extracellular matrix. Its important functions include mechanical rigidity of the skin, connective tissue resistance and tissue adhesion, support for cell adhesion, and cell division and differentiation. Induction (during the growth of organisms or wound healing) is known. Collagen decreases due to age and photoaging caused by ultraviolet irradiation, and collagen reduction is promoted by collagenase enzyme activity that decomposes collagen. This is known to be closely related to the formation of wrinkles on the skin.
또한, 엘라스틴(Elastin) 섬유는 콜라겐과 가교 결합을 형성하며 피부 탄력에 관여하고 있는 주름 생성에 중요한 피부 구성성분이다. 엘라스틴 섬유의 결핍과 응집, 엘라스틴 분해 효소인 엘라스타제(Elastase)의 활성도의 현격한 증가는 피부 주름 생성 요인 중의 하나로 밝혀지고 있다. 엘라스타제는 엘라스틴을 분해할 수 있는 유일한 효소로서 이에 대한 저해는 피부 주름 개선을 근본적으로 줄여줄 수 있다고 알려져 있다.In addition, elastin fibers form cross-links with collagen and are an important skin component in wrinkle formation, which is involved in skin elasticity. Deficiency and aggregation of elastin fibers and a significant increase in the activity of elastase, an elastin decomposing enzyme, have been found to be one of the factors causing skin wrinkles. Elastase is the only enzyme that can decompose elastin, and its inhibition is known to fundamentally reduce the improvement of skin wrinkles.
아울러, 콜라겐 및 엘라스틴 섬유는 진피층 내의 수분 보유에 중요한 역할을 하는 기질 단백질로 이러한 기질 단백질이 수분을 흡착하며, 이들이 이루는 구조 내부에 수분 보유력을 높여 피부가 적정 수분을 함유한 상태를 유지할 수 있도록 해주며, 이를 통해 피부의 탄력을 유지하는데 관여한다고 알려져 있다.In addition, collagen and elastin fibers are matrix proteins that play an important role in retaining moisture within the dermal layer. These matrix proteins absorb moisture and increase the moisture retention capacity within the structure they form, allowing the skin to maintain an appropriate level of moisture. It is known to be involved in maintaining skin elasticity.
현재, 피부 탄력 증진 및 주름 개선 화장료로는 레티노이드, 아데노신, 동물태반유래 단백질, 클로렐라 추출물 등이 알려져 있다. 가장 잘 알려져 있는 레티놀은 콜라겐 합성을 촉진하며 엘라스타제 효소를 저해하는 물질이지만 불안정하며, 피부 적용 시 자극, 발적 등의 안전성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 효과가 미미하여 실질적으로 피부 탄력 증진 및 주름 개선 효과를 기대하기가 어렵다고 알려져 있다.Currently, retinoids, adenosine, animal placenta-derived proteins, and chlorella extract are known as cosmetics for improving skin elasticity and improving wrinkles. The most well-known retinol is a substance that promotes collagen synthesis and inhibits the elastase enzyme, but it is unstable and its usage is limited due to safety issues such as irritation and redness when applied to the skin. It is known that it is difficult to expect the effect of improving elasticity and improving wrinkles.
당화(Glycation)는 일반적으로 효소의 관여 없이 일어나는 단백질 또는 지방에 포도당 또는 과당과 같은 단순당이 공유결합을 형성하는 반응을 의미한다. 최종당화산물의 축적은 단백질을 단단하고 더욱 부서지기 쉬운 상태로 변화시키며, 당화된 콜라겐은 진피층의 세포 외 기질에서 콜라겐이 적절한 구조를 형성하지 못하도록 함으로써 피부의 탄력을 잃게 하고 주름 생성을 촉진한다(Dyer, D. G. et al, The Journal of Clinical Investigation., 9, p. 2463, 1993). 또한 당화로 인해 생성된 최종당화산물은 갈색 빛을 띠는 물질로써, 피부 노화가 진행되면서 점차 얼굴빛이 노랗게 변하는 원인 물질로 생각되고 있으며, 특정 최종당화산물이 쌓일수록 피부에서 반사되는 반사 빛이 줄어든다고 알려져 있다(Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). 당화를 억제하는 물질로 아미노구아니딘(Aminoguanidine), 피리독사민(Pyridoxamine), 아스피린(Aspirin) 등이 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 효과를 기대할 수 없는 문제점이 있다.Glycation generally refers to a reaction in which a simple sugar such as glucose or fructose forms a covalent bond with a protein or fat without the involvement of enzymes. Accumulation of advanced glycation end products changes proteins into a hard and more brittle state, and glycated collagen prevents collagen from forming an appropriate structure in the extracellular matrix of the dermal layer, causing skin to lose elasticity and promoting the formation of wrinkles. Dyer, D. G. et al, The Journal of Clinical Investigation., 9, p. 2463, 1993). In addition, the advanced glycation end products produced by glycation are brown-colored substances, and are thought to be the cause of the face gradually turning yellow as skin aging progresses. As certain advanced glycation end products accumulate, the reflected light reflected from the skin decreases. It is known that (Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). Aminoguanidine, Pyridoxamine, and Aspirin are known as substances that inhibit glycation, but these substances have limits on the amount of use due to safety issues on the skin, or their effects are so minimal that they are practically effective. There is a problem that cannot be expected.
한편, 릴리오페사이드 비(liriopesides B)는 분자식 C39H62O12, 분자량 722.9를 가지는 스테로이드 계열의 화합물로서, 릴리오프롤리오사이드 비(lirioprolioside B) 또는 25(S)-루스코제닌-1-O-β-D-푸코피라노사이드-3-O-α-L-람노피라노시로도 명명된다. 맥문동(Liriopep latyphylla) 또는 개맥문동(Liriope spicata)으로부터 분리할 수 있으며, 피리딘, 메탄올, 에탄올 등의 용매에 녹는 것으로 알려져 있다.Meanwhile, liriopesides B is a steroid-based compound with the molecular formula C 39 H 62 O 12 and molecular weight 722.9, known as lirioprolioside B or 25( S )-ruscogenin-1. It is also called -O-β-D-fucopyranoside-3-O-α-L-rhamnopyranoside. Macmundong ( Liriopep latyphylla ) or Liriope spicata , and is known to be soluble in solvents such as pyridine, methanol, and ethanol.
이러한 배경하에, 본 발명자들은 미백 피부 미백, 피부 탄력 증진, 주름 개선 및 보습 효과가 우수한 물질에 관하여 연구를 수행하였으며, 이에 릴리오페사이드 비를 유효성분으로 포함하는 조성물이 멜라닌 총량 감소, 콜라겐 합성 촉진, 엘라스타제 및 콜라게네이즈 활성 저해, 항당화 및 항산화 효과를 나타냄을 규명하여, 이를 활용한 화장료 조성물, 식품 조성물 및 의약외품 조성물을 완성하기에 이르렀다.Against this background, the present inventors conducted research on substances with excellent skin whitening, skin elasticity enhancement, wrinkle improvement, and moisturizing effects. Accordingly, a composition containing liliopeside ratio as an active ingredient reduces the total amount of melanin and promotes collagen synthesis. , it was discovered that it inhibits elastase and collagenase activity, and exhibits anti-glycation and antioxidant effects, leading to the completion of cosmetic compositions, food compositions, and quasi-drug compositions using it.
본 발명의 목적은 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.The purpose of the present invention is to provide a cosmetic composition containing Liliopeside ratio represented by Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
구체적으로, 본 발명의 목적은 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공하는 것이다.Specifically, the purpose of the present invention is to provide a cosmetic composition for skin whitening containing Liliopeside ratio represented by Chemical Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공하는 것이다.Additionally, specifically, the purpose of the present invention is to provide a cosmetic composition for promoting skin elasticity or improving wrinkles, which contains liliopeside ratio represented by Chemical Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공하는 것이다.Additionally, specifically, the purpose of the present invention is to provide a cosmetic composition for moisturizing skin containing Liliopeside ratio represented by Chemical Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 다른 목적은 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition containing liliopeside ratio represented by Formula 1 or a foodologically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 의약외품 조성물을 제공하는 것이다.Another object of the present invention is to provide a quasi-drug composition containing liliopeside ratio represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명은 상기와 같은 과제들을 해결하고, 본 발명의 목적을 달성하기 위하여 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 화장료 조성물을 제공한다.In order to solve the above problems and achieve the object of the present invention, the present invention provides a cosmetic composition containing the compound represented by Formula 1 or a cosmetically acceptable salt thereof.
구체적으로, 본 발명의 하나의 양태로서, 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다.Specifically, as one aspect of the present invention, a cosmetic composition for skin whitening containing Liliopeside ratio represented by Chemical Formula 1 or a cosmetically acceptable salt thereof as an active ingredient is provided.
본 발명의 다른 양태로서, 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공한다.In another aspect of the present invention, a cosmetic composition for promoting skin elasticity or improving wrinkles is provided, which includes liliopeside ratio represented by Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 양태로서, 화학식 1로 표시되는 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공한다.In another aspect of the present invention, there is provided a cosmetic composition for moisturizing skin containing Liliopeside ratio represented by Chemical Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 양태로서, 릴리오페사이드 비 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 식품 조성물을 제공한다.In another aspect of the present invention, a food composition is provided comprising liliopeside ratio or a foodologically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 양태로서, 릴리오페사이드 비 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 의약외품 조성물을 제공한다.In another aspect of the present invention, a quasi-drug composition containing liliopeside ratio or a pharmaceutically acceptable salt thereof as an active ingredient is provided.
본 발명에서는 하기 화학식 1로 표시되는 릴리오페사이드 비 화합물 또는 이의 염을 포함하는 조성물을 제공한다.The present invention provides a composition containing a liliopeside ratio compound represented by the following formula (1) or a salt thereof.
[화학식 1] [Formula 1]
본 발명에 있어서, “릴리오페사이드 비(liriopesides B)”는 상기 화학식 1로 표시되고, 분자식 C39H62O12, 분자량 722.9를 가지며, 릴리오페사이드 비(liriopesides B), 릴리오프롤리오사이드 비(lirioprolioside B) 또는 25(S)-루스코제닌-1-O-β-D-푸코피라노사이드-3-O-α-L-람노피라노시(25(S)-ruscogenin-1-O-β-Dfucopyranoside-3-O-α-L-rhamnopyranosy)로 명명되는 화합물로, 맥문동(Liriopep latyphylla) 또는 개맥문동(Liriope spicata)에 함유된 스테로이드(steroid)로 분류되는 유기화합물이다.In the present invention, “liriopesides B” is represented by the above formula (1), has a molecular formula of C 39 H 62 O 12 , and a molecular weight of 722.9. Liriopesides B, lirioprolioside B (lirioprolioside B) or 25( S )-ruscogenin-1-O-β-D-fucopyranoside-3-O-α-L-rhamnopyranoside (25( S )-ruscogenin-1-O -β-Dfucopyranoside-3-O-α-L-rhamnopyranosy) is an organic compound classified as a steroid contained in Liriopep latyphylla or Liriope spicata .
상기 맥문동은 Liriope platyphylla, Liriopep latyphylla 또는 Liriope spicata라고도 불리는 백합과(family liliaceae)의의 여러해살이 식물종으로 전세계에 널리 존재한다. 짧고 굵은 뿌리줄기에서 잎이 모여 나와서 포기를 형성하고, 흔히 뿌리 끝이 커져서 땅콩같이 된다. 줄기는 곧게 서며 높이가 20 ~ 50 cm이다. 잎은 짚은 녹색을 띠고 선형이며 길이는 30 ~ 40 cm, 나비는 8 ~ 12 mm 이고 밑부분이 잎집처럼 된다. 한방에서 약재로 사용되는 맥문동 뿌리에는 베타 시토스테롤, 스티그마 스테롤, 스테로이드 사포닌, 아미노산 등의 성분을 포함하는 것으로 알려져 있다.The above Macmundong is Liriope platyphylla , Liriopep Also called latyphylla or Liriope spicata, it is a perennial plant species of the family liliaceae and is widespread around the world. Leaves come together from the short, thick rhizome to form a shoot, and the tip of the root often becomes large and resembles a peanut. The stem stands erect and is 20 to 50 cm high. The leaves are straw green, linear, 30 to 40 cm long, 8 to 12 mm wide, and the lower part is like a leaf sheath. Macmundong root, which is used as a medicinal herb in oriental medicine, is known to contain ingredients such as beta sitosterol, stigma sterol, steroid saponin, and amino acids.
본 발명은 릴리오페사이드 비의 획득 방법에 특별히 한정되지 않으며, 당업계에 공지된 방법으로 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다.The present invention is not particularly limited to the method of obtaining liliopeside ratio, and it can be chemically synthesized by a method known in the art, or a commercially available material can be used.
본 발명의 화학식 1로 표시되는 릴리오페사이드 비는 수화물, 에탄올화물 등의 형태를 포함하는 용매화된 형태뿐만 아니라 비-용매화된(unsolvated) 형태로 존재할 수도 있다. 본 발명의 릴리오페사이드 비는 결정형 또는 무정형 형태로 존재할 수 있으며, 이러한 모든 물리적 형태는 본 발명의 범위에 포함된다.Liliopeside ratio represented by Formula 1 of the present invention may exist in an unsolvated form as well as a solvated form including hydrate, ethanolate, etc. The liliopeside ratio of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.
본 발명에 따른 조성물에 있어, 상기 릴리오페사이드 비의 함량은 조성물 전체 중량 대비 0.0001 내지 10 중량% 인 것이 바람직하다.In the composition according to the present invention, the content of the lillopeside ratio is preferably 0.0001 to 10% by weight based on the total weight of the composition.
본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition containing the compound represented by Formula 1 or a cosmetically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 또는 피부 보습용 화장료 조성물을 제공할 수 있다.Additionally, specifically, the present invention can provide a cosmetic composition for skin whitening, improving skin elasticity or wrinkles, or moisturizing the skin, comprising the compound represented by Formula 1 or a cosmetically acceptable salt thereof.
본 발명에 있어서, “피부 미백”이라 함은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 말한다. 본 발명의 일 실시예에서는, 화학식 1로 표시되는 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)에 첨가한 후 멜라닌 총량을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 양성대조군에 비하여 상당히 우수한 멜라닌 총량 감소 효과를 나타내어, 화학식 1로 표시되는 화합물을 포함하는 조성물은 피부 미백 용도로 사용될 수 있음을 확인하였다(실험예 1).In the present invention, “skin whitening” refers to not only brightening skin tone by inhibiting the synthesis of melanin pigment, but also improving skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, or genetics. In one embodiment of the present invention, the total amount of melanin was measured after adding the compound represented by Formula 1 to mouse melanoma cells (B-16 mouse melanoma cells). As a result, the experimental group to which the compound was added was compared to the positive control group. It was confirmed that the composition containing the compound represented by Formula 1 can be used for skin whitening by showing a significantly superior effect in reducing the total amount of melanin compared to that of the composition (Experimental Example 1).
본 발명에 있어서, “피부 탄력 증진”이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것으로, 엘라스틴으로 구성된 탄력섬유가 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력이 유지되는 것을 말한다. 본 발명에 있어서, “주름 개선”이란 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present invention, “promoting skin elasticity” refers to alleviating the degree of sagging or sagging of the skin, where elastic fibers composed of elastin exist together with collagen fibers called collagen, and elastin and collagen are sufficiently present. This means that skin elasticity is maintained in this condition. In the present invention, “wrinkle improvement” refers to suppressing or inhibiting the formation of wrinkles on the skin or alleviating wrinkles that have already formed.
본 발명의 일 실시예에서는, 화학식 1로 표시되는 화합물을 인간 유래 섬유아세포의 배양액에 첨가한 후 콜라겐 합성 촉진 효과를 실험한 결과, 상기 화합물을 첨가한 실험군의 경우 양성대조군에 비하여 더 낮은 농도에서 유사한 콜라겐 합성 효과를 나타내었다(실험예 2). 또한, 본 발명의 일 실시예에서는, 상기 화학식 1로 표시되는 화합물의 엘라스타제 및 콜라게네이즈 활성 저해 효과를 실험한 결과, 릴리오페사이드 비를 첨가한 실험군의 경우 우수한 엘라스타제 및 콜라게네이즈 활성 저해 효과를 나타내었다(실험예 3 및 4). 이를 통해, 화학식 1로 표시되는 화합물을 포함하는 조성물은 피부 탄력 증진 또는 주름 개선 용도로 사용될 수 있음을 확인하였다.In one embodiment of the present invention, the effect of promoting collagen synthesis was tested after adding the compound represented by Formula 1 to the culture medium of human-derived fibroblasts. As a result, the experimental group to which the compound was added had a lower concentration than the positive control group. A similar collagen synthesis effect was shown (Experimental Example 2). In addition, in one embodiment of the present invention, as a result of testing the inhibitory effect of the compound represented by Formula 1 on elastase and collagenase activity, the experimental group to which Liliopeside ratio was added showed excellent elastase and collagenase activity. It showed an inhibitory effect on enzyme activity (Experimental Examples 3 and 4). Through this, it was confirmed that a composition containing the compound represented by Formula 1 can be used for improving skin elasticity or improving wrinkles.
본 발명에 있어서, “피부 보습”이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 피부 보습 효과는 피부의 주름개선, 탄력도 증가에 도움을 줄 수 있다. 본 발명의 일 실시예에서는, 상기 화학식 1로 표시되는 화합물의 우수한 콜라겐 합성 효과, 엘라스타제 및 콜라게네이즈 활성 저해 효과를 나타내었는바, 화학식 1로 표시되는 화합물 포함하는 조성물은 피부 보습 용도로 사용될 수 있음을 확인하였다(실험예 2 내지 4).In the present invention, “skin moisturizing” means increasing moisture in the skin and maintaining a moist state. The skin moisturizing effect can help improve skin wrinkles and increase elasticity. In one embodiment of the present invention, the compound represented by Formula 1 showed an excellent collagen synthesis effect and an inhibitory effect on elastase and collagenase activities, and the composition containing the compound represented by Formula 1 was used for skin moisturizing purposes. It was confirmed that it could be used (Experimental Examples 2 to 4).
본 발명에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention includes solution, external ointment, cream, foam, nourishing lotion, softening lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid cleanser, bath agent, sunscreen cream, sun oil, suspension, Can be prepared in a formulation selected from the group consisting of emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays. That is not the case.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may additionally include one or more cosmetically acceptable carriers that are blended with general skin cosmetics, and common ingredients include, for example, oil, water, surfactant, moisturizer, lower alcohol, Thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be appropriately mixed, but are not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.Cosmetically acceptable carriers included in the cosmetic composition of the present invention vary depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, paste, cream or gel, the carrier ingredient may be animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures of these can be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silcate, polyamide powder, or mixtures thereof may be used as the carrier ingredient, and especially in the case of a spray, chloro May contain propellants such as fluorohydrocarbons, propane/butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-Butylglycol oil may be used, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. there is.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and miso. Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is soap, alkali metal salts of fatty acids, hemiester salts of fatty acids, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. may be used as carrier ingredients. You can.
또한, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 식품 조성물을 제공한다.Additionally, the present invention provides a food composition containing the compound represented by Formula 1 or a foodologically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 또는 피부 보습용 식품 조성물을 제공할 수 있다. 상기 화학식 1로 표시되는 릴리오페사이드 비 화합물, 피부 미백, 피부 탄력 증진, 주름 개선, 및 피부 보습은 상기에서 설명한 바와 같다. 상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되는 것은 아니다.Additionally, specifically, the present invention can provide a food composition for skin whitening, improving skin elasticity or wrinkles, or moisturizing the skin, comprising the compound represented by Formula 1 or a foodologically acceptable salt thereof. Liliopeside non-compound represented by Chemical Formula 1, skin whitening, skin elasticity enhancement, wrinkle improvement, and skin moisturization are as described above. The food composition may be used in the form of a health functional food, but is not limited thereto.
본 발명의 식품 조성물에 포함된 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염은 화학식 1로 표시되는 화합물을 포함하는 동식물, 이의 추출물, 이의 분획물 또는 이의 가공물의 형태로 포함될 수 있다. 또한 상기 조성물은 유효성분 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The compound represented by Formula 1 or a foodologically acceptable salt thereof contained in the food composition of the present invention may be included in the form of animals or plants containing the compound represented by Formula 1, extracts thereof, fractions thereof, or processed products thereof. Additionally, the composition may include food additives that are foodologically acceptable in addition to the active ingredients.
본 발명에 있어서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.In the present invention, “food supplement” refers to a component that can be added to food as an auxiliary ingredient, and can be appropriately selected and used by a person skilled in the art as it is added to manufacture each type of health functional food. Examples of food supplements include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, and protective colloidal thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., but the types of food supplements of the present invention are not limited to the above examples.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 “기능성”이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부 미백, 피부 탄력 증진 또는 주름 개선, 또는 피부 보습 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The food composition of the present invention may include health functional foods. In the present invention, “health functional food” refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and pills using raw materials or ingredients with functional properties useful to the human body. Here, “functionality” means controlling nutrients for the structure and function of the human body or obtaining useful effects for health purposes, such as physiological effects. The health functional food of the present invention can be manufactured by a method commonly used in the industry, and can be manufactured by adding raw materials and components commonly added in the industry. Additionally, the formulation of the health functional food can also be manufactured without limitation as long as it is a formulation recognized as a health functional food. The food composition of the present invention can be manufactured in various types of formulations, and unlike general drugs, it has the advantage of being made from food as a raw material and has no side effects that may occur when taking the drug for a long period of time, and is excellent in portability, making it suitable for use in the formulation of the present invention. Health functional foods can be taken as supplements to whiten skin, improve skin elasticity, improve wrinkles, or improve skin moisturization.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 화학식 1로 표시되는 화합물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.There is no limit to the form that the health functional food of the present invention can take, and it can include all foods in the conventional sense and can be used interchangeably with terms known in the art, such as functional food. In addition, the health functional food of the present invention can be manufactured by mixing known additives with other appropriate auxiliary ingredients that can be included in the food according to the selection of a person skilled in the art. Examples of foods that can be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes, etc., and they can be prepared by adding the compound represented by Chemical Formula 1 according to the present invention to juices, teas, jellies, etc. prepared as main ingredients. It also includes foods used as feed for animals.
또한, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 의약외품 조성물을 제공한다.Additionally, the present invention provides a quasi-drug composition containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 또는 피부 보습용 의약외품 조성물을 제공할 수 있다. 상기 화학식 1로 표시되는 릴리오페사이드 비 화합물, 피부 미백, 피부 탄력 증진, 주름 개선, 및 피부 보습은 상기에서 설명한 바와 같다.Additionally, specifically, the present invention can provide a quasi-drug composition for skin whitening, improving skin elasticity or wrinkles, or moisturizing the skin, comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof. Liliopeside non-compound represented by Chemical Formula 1, skin whitening, skin elasticity enhancement, wrinkle improvement, and skin moisturization are as described above.
본 발명의 의약외품 조성물에는 상기 성분 외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.In addition to the above ingredients, the quasi-drug composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents as needed. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effect of the present invention, and includes, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. It can be included.
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of pharmaceutically acceptable carriers, excipients or diluents of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, gum acacia, alginate, calcium phosphate, calcium. Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil. , injectable esters, Wethepsol, Macrogol, Tween 61, Kakaoji, Lauridge, etc.
또한, 본 발명의 화학식 1로 표시되는 화합물을 의약외품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 미백, 탄력 증진, 주름 개선 및 보습 성분을 포함할 수 있을 것이다. 추가적인 피부 미백, 탄력 증진, 주름 개선 및 보습 성분을 포함하게 되면 본 발명의 조성물의 피부 미백, 탄력 증진, 주름 개선 및 보습 효과는 더욱 증가될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 상기 의약외품 조성물은 당업계에 공지된 미백 성분으로서, 코즈산(Kojic acid), 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민-C(L-Ascorbic acid); 당업계에 공지된 피부 탄력, 주름 개선 또는 보습 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물; 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 피부 안전성, 상기 화학식 1로 표시되는 화합물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.In addition, when the compound represented by Formula 1 of the present invention is used as a quasi-drug, it may additionally contain one or more active ingredients showing the same or similar functions. For example, it may contain known skin whitening, elasticity enhancement, wrinkle improvement, and moisturizing ingredients. If additional skin whitening, elasticity enhancement, wrinkle improvement, and moisturizing ingredients are included, the skin whitening, elasticity enhancement, wrinkle improvement, and moisturizing effects of the composition of the present invention can be further increased. When adding the above ingredients, skin safety due to combined use, ease of formulation, and stability of the active ingredients can be taken into consideration. The quasi-drug composition includes whitening ingredients known in the art, such as substances that inhibit tyrosinase enzyme activity such as Kojic acid and Arbutin, Hydroquinone, Vitamin-C (L-Ascorbic acid); Skin elasticity, wrinkle improvement or moisturizing ingredients known in the art include retinoic acid, TGF, protein from animal placenta, betulinic acid and chlorella extract; and one or two or more ingredients selected from the group consisting of their derivatives and various plant extracts. Additional ingredients may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety and ease of formulation of the compound represented by Formula 1. will be.
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention may include, but is not limited to, disinfectant cleaner, shower foam, ointment, wet tissue, coating agent, etc., and the formulation method, dosage, usage method, and components of the quasi-drug are commonly known in the technical field. It can be appropriately selected from the techniques.
또한, 본 발명의 상기 화학식 1로 표시되는 화합물은 개체의 피부에 도포하는 단계를 포함하는, 피부 미백, 피부 탄력 증진 또는 주름 개선, 또는 피부 보습 방법에 사용될 수 있다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함한다.In addition, the compound represented by Formula 1 of the present invention can be used in a method for skin whitening, improving skin elasticity or wrinkles, or moisturizing the skin, which includes the step of applying it to the skin of an individual. The subject includes mammals, including rats, livestock, humans, etc., without limitation.
본 발명의 릴리오페사이드 비 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물은 피부 미백, 탄력 증진 또는 주름 개선, 피부 보습 효능이 우수하다. 구체적으로 본 발명의 조성물은 항당화 및 항산화 효과가 우수하며, 저농도에서도 뛰어난 멜라닌 총량 감소 효과를 나타내고 콜라겐 합성 촉진 효과, 엘라스타제 및 콜라게네이즈 활성 저해 효과가 우수하여 피부 미백용, 탄력 증진용 또는 주름 개선용, 및 피부 보습용 화장료 조성물로서의 활용도가 높다. 또한, 본 발명의 릴리오페사이드 비를 포함하는 조성물은 식품 조성물 및 의약외품 조성물로서 사용할 수 있다.The cosmetic composition containing Liliopeside B or a cosmetically acceptable salt thereof of the present invention as an active ingredient has excellent skin whitening, elasticity improvement or wrinkle improvement, and skin moisturizing effects. Specifically, the composition of the present invention has excellent anti-glycation and antioxidant effects, has an excellent effect of reducing the total amount of melanin even at low concentrations, has an excellent effect of promoting collagen synthesis and inhibiting elastase and collagenase activity, and is used for skin whitening and elasticity enhancement. Alternatively, it has high utility as a cosmetic composition for improving wrinkles and moisturizing the skin. Additionally, the composition containing Liliopeside ratio of the present invention can be used as a food composition and quasi-drug composition.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention and the scope of the present invention is not limited by these examples.
참조예 1 : 릴리오페사이드 비(liriopesides B) 물질 정보Reference Example 1: Liriopesides B Material Information
[화학식 1][Formula 1]
물질명 : Liriopesides BSubstance name: Liriopesides B
CAS No. : 87425-34-1CAS No. : 87425-34-1
분자식 : C39H62O12 Molecular formula: C 39 H 62 O 12
분자량 : 722.9Molecular Weight: 722.9
구입처 : Chengdu Herbpurify CO.,LTDWhere to buy: Chengdu Herbpurify CO.,LTD
실험예 1 : 세포 수준에서의 멜라닌 총량 감소 효과에 따른 미백 효과Experimental Example 1: Whitening effect according to the effect of reducing the total amount of melanin at the cellular level
화학식 1의 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포 수준에서의 멜라닌 총량을 측정함으로써 미백 효과를 확인하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980). 실험 전 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도를 선정하여 미백 평가를 수행하였다.The whitening effect was confirmed by adding the compound of Formula 1 to the culture medium of B-16 mouse melanoma cells and measuring the total amount of melanin at the cellular level (Lotan R., Lotan D. Cancer Res . 40: 3345-3350, 1980). Before the experiment, toxicity was evaluated for rat melanoma cells, a non-toxic concentration was selected, and whitening evaluation was performed.
화학식 1의 화합물을 배양액에 최종 농도가 1 ppm 또는 10 ppm이 되도록 하였으며, 대조군인 알부틴은 100 ppm이 되도록 첨가하여 각각 B-16 멜라노마 세포에 처리한 후 3일간 배양하였다.The compound of Formula 1 was added to the culture medium to a final concentration of 1 ppm or 10 ppm, and arbutin as a control was added to 100 ppm, treated with B-16 melanoma cells, and cultured for 3 days.
이후, 세포들을 트립신(trypsin) 처리하여 배양용기로부터 떼어내 원심분리한 후, 멜라닌을 추출하였다. 떼어낸 세포는 수산화나트륨 용액(1N 농도) 1 ml를 가하여 10 분간 끓여 멜라닌을 녹이고 분광 광도계를 이용하여 400 nm에서 흡광도를 측정함으로써 생성된 멜라닌의 양을 측정하였다.Afterwards, the cells were treated with trypsin, removed from the culture vessel, centrifuged, and melanin was extracted. To the removed cells, 1 ml of sodium hydroxide solution (1N concentration) was added and boiled for 10 minutes to dissolve the melanin. The amount of melanin produced was measured by measuring the absorbance at 400 nm using a spectrophotometer.
상기 멜라닌 양은 단위 세포수당(1×106 cell)의 흡광도로 나타내는 방법으로 측정하였으며, 대조군에 대한 상대적인 멜라닌 총량을 저해율(%)로 계산하고 결과를 하기 표 1에 정리하였다.The amount of melanin was measured by expressing the absorbance per unit cell (1×10 6 cell). The total amount of melanin relative to the control group was calculated as the inhibition rate (%), and the results are summarized in Table 1 below.
상기 표 1의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 양성대조군인 알부틴과 비교했을 때, 1/10 수준의 저농도인 10 ppm에서도 상당히 우수한 멜라닌 총량 감소 효과를 나타내어, 피부 미백 용도로 사용할 수 있음을 알 수 있었다.As can be seen from the results in Table 1, the compound of Chemical Formula 1 shows a significantly excellent effect of reducing the total amount of melanin even at a concentration as low as 1/10 of 10 ppm compared to arbutin, a positive control, and can be used for skin whitening. And it was found.
실험예Experiment example 2 : 인체 유래의 섬유아세포에서 제1형 콜라겐(type Ⅰ collagen) 합성 촉진 효과 2: Effect of promoting type 1 collagen synthesis in human-derived fibroblasts
화학식 1의 화합물을 인간 유래 섬유아세포의 배양액에 첨가하여 세포 수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type Ⅰ C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다. 콜라겐 합성량을 측정하기 위해 화학식 1의 화합물을 섬유아세포의 배양배지(DMEM 배지)에 첨가하여 48 시간 배양한 후 배양액을 취하여 PICP EIA 키트로 저농도에서 제1형 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다.The compound of Formula 1 was added to the culture medium of human-derived fibroblasts, and the effect of promoting type 1 collagen synthesis was confirmed at the cellular level. The synthesized collagen was quantified using the PICP EIA kit (Procollagen Type Ⅰ C-Peptide Enzyme Immuno Assay KIT). To measure the amount of collagen synthesis, the compound of formula 1 was added to the culture medium (DMEM medium) of fibroblasts and cultured for 48 hours, then the culture medium was taken and the degree of type 1 collagen synthesis was measured at low concentration using a PICP EIA kit using a spectrophotometer. Measured at 450 nm.
효과의 비교를 위하여 시료를 처리하지 않은 섬유아세포의 배양배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 μg/ml 가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성 증가율은 대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 2에 나타내었다.To compare the effects, the degree of collagen synthesis was measured using the same method for samples to which untreated fibroblast culture medium (negative control) and vitamin C (positive control) were added to a final concentration of 52.85 μg/ml. The rate of increase in collagen production was calculated as the ratio of collagen production relative to the control group, and the results are shown in Table 2 below.
상기 표 2의 결과에서 볼 수 있듯이, 화학식 1의 화합물을 처리한 경우, 농도 의존적으로 콜라겐 합성이 증가되었고, 일반적으로 콜라겐 합성을 유도하는 것으로 잘 알려진 비타민 C를 적용한 경우보다 더 낮은 농도에서 유사한 콜라겐 합성 효과를 나타내었다. 따라서, 화학식 1의 화합물은 피부 탄력 증진, 주름 개선 또는 피부 보습 용도로 사용할 수 있음을 알 수 있었다. As can be seen from the results in Table 2, when treated with the compound of Formula 1, collagen synthesis increased in a concentration-dependent manner, and similar collagen was produced at a lower concentration than when vitamin C, which is generally known to induce collagen synthesis, was applied. It showed a synthetic effect. Accordingly, it was found that the compound of Formula 1 can be used to improve skin elasticity, improve wrinkles, or moisturize the skin.
실험예 3 : 엘라스타제 활성 저해 효과 (반복수 = 3)Experimental Example 3: Elastase activity inhibition effect (number of repetitions = 3)
엘라스틴(elastin)을 분해하는 효소인 엘라스타제(elastase)의 활성 저해 효과를 다음과 같이 확인하였다.The effect of inhibiting the activity of elastase, an enzyme that decomposes elastin, was confirmed as follows.
엘라스타제(elastase)는 사람의 백혈구 세포로부터 유래한 엘라스타제를 사용하였고, 엘라스타제의 기질로 합성 기질인 MeOSuc-Ala-Ala-Pro-Val-pNA를 사용하였다. 완충용액은 100 mM의 Tris (pH 7.5) 용액을 사용하였다. 엘라스타제는 완충용액을 이용하여 최종적으로 0.2 mU 을 사용하였다. 또한 엘라스타제의 합성 기질은 DMSO를 이용하여 100 mM 용액을 만든 후 최종 농도가 0.5 mM이 되도록 완충용액을 이용하여 희석하였다. 이 때, 양성 대조군은 엘라스테이즈 저해 물질로 알려진 퀘르세틴(Quercetin)을 10 ppm 농도로 넣은 것으로 설정하였다. 엘라스타제 저해 후보는 최종농도가 10, 20 ppm이 되도록 첨가하였다. 반응은 96-웰 플레이트에서 진행하였으며, 상온에서 20 분간 반응시켰다. 분광 광도계를 이용하여 1 분 간격으로 405 nm에서 흡광도를 측정하여, 시간 대비 흡광도의 기울기를 구하여 효소의 활성도를 측정하였다. 엘라스타제 저해율은 다음과 같이 계산하였으며, 그 결과는 하기 표 3에 나타내었다.Elastase derived from human white blood cells was used, and the synthetic substrate MeOSuc-Ala-Ala-Pro-Val-pNA was used as the elastase substrate. A 100mM Tris (pH 7.5) solution was used as the buffer solution. Elastase was used in a final amount of 0.2 mU using a buffer solution. In addition, the synthetic substrate of elastase was made into a 100mM solution using DMSO and then diluted with a buffer solution to reach a final concentration of 0.5mM. At this time, the positive control was set to contain quercetin, known as an elastase inhibitor, at a concentration of 10 ppm. Elastase inhibition candidates were added to final concentrations of 10 and 20 ppm. The reaction was carried out in a 96-well plate and reacted at room temperature for 20 minutes. Absorbance was measured at 405 nm at 1 minute intervals using a spectrophotometer, and the slope of absorbance versus time was obtained to measure enzyme activity. The elastase inhibition rate was calculated as follows, and the results are shown in Table 3 below.
상기 표 3의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 10 ppm의 농도에서 엘라스타제 활성 저해 효과가 양성대조군인 퀘르세틴에 상응하는 정도로 높게 나타났으며, 20 ppm의 농도에서 퀘르세틴보다 우수한 엘라스타제 활성 저해 효과가 나타나, 화학식 1의 화합물은 엘라스타제 활성 저해 효과가 우수함을 확인하였다. 따라서, 화학식 1의 화합물은 피부 탄력 증진, 주름 개선 또는 피부 보습 용도로 사용할 수 있음을 알 수 있었다. As can be seen from the results in Table 3, the compound of Chemical Formula 1 showed a high elastase activity inhibition effect at a concentration of 10 ppm, comparable to that of quercetin, a positive control, and showed superior elastase activity to quercetin at a concentration of 20 ppm. It was confirmed that the compound of Formula 1 has an excellent effect of inhibiting elastase activity. Accordingly, it was found that the compound of Formula 1 can be used to improve skin elasticity, improve wrinkles, or moisturize the skin.
실험예 4 : 콜라게네이즈 활성 저해 효과 (반복수 = 3)Experimental Example 4: Effect of inhibiting collagenase activity (number of repetitions = 3)
콜라겐(collagen)을 분해하는 효소인 콜라게네이즈의 활성 저해 효과를 다음과 같이 확인하였다.The effect of inhibiting the activity of collagenase, an enzyme that decomposes collagen, was confirmed as follows.
콜라게네이즈는 쥐의 이자에서 유래한 콜라게네이즈를 사용하였고, 콜라게네이즈의 기질로 합성 기질인 N-(3-[2-Furyl]acryloyl)-Leu-Gly-Pro-Ala을 사용하였다. 완충용액은 50mM Tricine, 10mM CaCl2·H2O, 400mM NaCl(pH 7.5)이 녹아 있는 용액을 사용하였다. 합성 기질은 완충용액을 이용하여 10 mM의 농도로 녹인 후 최종적으로 75 μM이 되도록 희석하였다. 콜라게네이즈는 4 ℃의 차가운 3차 증류수를 이용하여 1 unit/ml 농도로 녹인 후 최종적으로 0.05 unit/ml이 되도록 완충용액을 이용하여 희석하였다. 콜라게네이즈 저해 후보는 최종농도 10, 20 ppm에서 실험하였다. 이 때, 양성 대조군은 콜라게네이즈 저해 효과가 알려진 에피갈로카테킨 갈레이트(EGCG)를 최종농도 10 ppm이 되도록 설정하였다. 반응은 96-웰 플레이트에서 진행하였으며, 상온에서 10분간 반응시켰다. 분광 광도계를 이용하여 1분 간격으로 345 nm에서 흡광도를 측정하여 시간 대비 흡광도의 최대 기울기를 구하여 효소의 활성으로 정하였다. 콜라게네이즈 저해율은 다음과 같이 계산하였으며, 그 결과는 하기 표 4에 나타내었다.Collagenase derived from rat pancreas was used, and the synthetic substrate N-(3-[2-Furyl]acryloyl)-Leu-Gly-Pro-Ala was used as the collagenase substrate. A buffer solution containing 50mM Tricine, 10mM CaC l2 ·H 2O , and 400mM NaCl (pH 7.5) was used. The synthetic substrate was dissolved to a concentration of 10 mM using a buffer solution and then diluted to a final concentration of 75 μM. Collagenase was dissolved at a concentration of 1 unit/ml using cold tertiary distilled water at 4°C and then diluted with a buffer solution to a final concentration of 0.05 unit/ml. Collagenase inhibition candidates were tested at final concentrations of 10 and 20 ppm. At this time, the positive control group was epigallocatechin gallate (EGCG), which is known to have a collagenase inhibitory effect, and was set to a final concentration of 10 ppm. The reaction was carried out in a 96-well plate and reacted at room temperature for 10 minutes. Absorbance was measured at 345 nm at 1 minute intervals using a spectrophotometer, and the maximum slope of absorbance versus time was determined to be the enzyme activity. The collagenase inhibition rate was calculated as follows, and the results are shown in Table 4 below.
상기 표 4의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 20 ppm의 농도에서 양성대조군인 EGCG보다 우수한 콜라게네이즈 활성 저해 효과가 나타나, 화학식 1의 화합물은 콜라게네이즈 효과가 우수함을 확인하였다. 따라서, 화학식 1의 화합물은 피부 탄력 증진, 주름 개선 또는 피부 보습 용도로 사용할 수 있음을 알 수 있었다.As can be seen from the results in Table 4, the compound of Formula 1 showed a better effect of inhibiting collagenase activity than EGCG, the positive control, at a concentration of 20 ppm, confirming that the compound of Formula 1 had an excellent collagenase effect. Accordingly, it was found that the compound of Formula 1 can be used to improve skin elasticity, improve wrinkles, or moisturize the skin.
실험예 5 : 항당화(anti-glycation) 효과Experimental Example 5: Anti-glycation effect
항당화(anti-glycation) 효능을 확인하기 위하여, L-아르기닌(arginine)과 포도당을 이용하여 항당화 활성을 측정하였다.To confirm the anti-glycation effect, the anti-glycation activity was measured using L-arginine and glucose.
먼저, 1M 인산 완충용액(pH 7.4)을 이용하여 1M L-아르기닌(arginine), 1M 포도당을 녹여 준비하고 1M 인산 완충용액을 이용하여 시료를 25, 50 ppm이 되도록 희석해서 준비하였다. 1M L-아르기닌과 1M 인산 완충용액을 1 대 4의 비율로 섞은 다음 96-웰 플레이트에 80 μl씩 분주하였다. 여기에 각각 25, 50 ppm으로 희석한 시료와 양성 대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100 μl씩 첨가하였다. 이 시료들을 잘 섞어준 다음, 마지막으로 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충용액으로 희석한 포도당을 넣은 후, 70 ℃에서 4 시간 동안 반응시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420 nm에서 흡광도를 측정하여 당화 정도를 측정하였다.First, 1M L-arginine and 1M glucose were prepared by dissolving them in 1M phosphate buffer solution (pH 7.4), and the sample was diluted to 25 and 50 ppm using 1M phosphate buffer solution. 1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1 to 4, and then 80 μl each was dispensed into a 96-well plate. Here, 100 μl of samples diluted to 25 and 50 ppm, respectively, and 0.01M aminoguanidin to be used as a positive control were added. These samples were mixed well, and finally, glucose diluted with 1M phosphate buffer solution was added so that the final concentration of glucose was 0.1M, and then reacted at 70°C for 4 hours. The degree of glycosylation was measured by measuring the absorbance of the 96-well plate at 420 nm using a spectrophotometer.
하기 식의 당화(glycation) 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420 nm에서 흡광도를 측정하였다. 당화 저해 활성은 다음과 같은 식으로 구하였으며, 그 결과는 하기 표 5에 나타내었다.The glycation experimental group shown below is an experimental group in which 1M L-arginine and 1M glucose were added to induce glycation. To measure the absorbance of the sample itself, only 1M L-arginine and the sample were added without adding glucose and the absorbance was measured at 420 nm. Measured. The glycation inhibition activity was calculated as follows, and the results are shown in Table 5 below.
상기 표 5의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 항당화 물질로 알려진 아미노구아니딘과 비교할 때, 항당화 효과가 더욱 뛰어남을 알 수 있었다. 따라서, 화학식 1의 화합물은 우수한 항당화 효과를 나타내어, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다.As can be seen from the results in Table 5, the compound of Formula 1 was found to have a more excellent anti-glycation effect compared to aminoguanidine, a known anti-glycation substance. Therefore, it was found that the compound of Formula 1 exhibits an excellent anti-glycation effect and acts as an auxiliary agent in skin whitening, improving elasticity, improving wrinkles, and moisturizing the skin, so a synergistic effect can be expected.
실험예 6 : 항산화 효과 - 자유라디칼 소거율Experimental Example 6: Antioxidant effect - free radical scavenging rate
화학식 1의 물질의 항산화 작용을 확인하기 위해 자유라디칼 소거 활성을 측정하였다. 자유라디칼 소거 활성은 DPPH를 이용하여 측정하였다. DPPH는 시그마사(Sigma Co., Ltd, 미국)에서 구입하여 사용하였다. 먼저, 1.5 mM (0.06 mg/ml)의 표준 DPPH 에탄올 용액을 만들었다. 그리고, 3차 증류수를 이용하여 1000 μg/ml 비타민 C 용액을 만든 다음 1/2씩 연속 희석하여 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625, 1.953125, 0.9765625, 0.48828125 μg/ml 농도의 비타민 C 시료를 만들었다. 또한 비타민 C와 동일한 농도로 화학식 1의 희석액을 준비하였다. 그 다음, 상기 시료와 표준 DPPH 용액을 같은 비율로 첨가하여 잘 교반한 후, 37 ℃에서 30 분간 반응시키고 520 ㎚에서 흡광도를 측정하였다. 이때, 상기 시료 대신 에탄올을 첨가한 것을 대조군으로 하였다. 자유라디칼 소거능은 half maximal inhibitory concentration(억제 중간 값)인 IC50을 구하여 그 결과를 하기 표 6에 나타내었다. IC50은 무첨가 대조군의 자유라디칼을 50% 제거하는데 필요한 비타민 C 및 화학식 1의 화합물의 농도로써 자유라디칼 소거능을 표현하는 일반적인 방법이다.To confirm the antioxidant activity of the substance of Formula 1, free radical scavenging activity was measured. Free radical scavenging activity was measured using DPPH. DPPH was purchased and used from Sigma Co., Ltd (USA). First, a standard DPPH ethanol solution of 1.5 mM (0.06 mg/ml) was prepared. Then, make a 1000 μg/ml vitamin C solution using distilled water and then serially dilute it by 1/2 to 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625, 1.953125, 0.9765625, 0.488281. 25 μg/ A sample of vitamin C at a concentration of ml was prepared. Additionally, a diluted solution of Formula 1 was prepared with the same concentration as vitamin C. Next, the sample and the standard DPPH solution were added in equal proportions, stirred well, reacted at 37°C for 30 minutes, and absorbance was measured at 520 nm. At this time, ethanol was added instead of the above sample as a control. The free radical scavenging ability was calculated as IC 50 , which is the half maximal inhibitory concentration (median inhibition value), and the results are shown in Table 6 below. IC 50 is a general method of expressing free radical scavenging ability as the concentration of vitamin C and the compound of formula 1 required to remove 50% of free radicals in the no-added control group.
상기 표 6의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 일반적으로 항산화 물질로 알려진 비타민 C를 적용한 경우보다 더 낮은 IC50 값을 지님을 알 수 있었다. 따라서, 화학식 1의 화합물은 우수한 항산화 효과를 나타내어, 항당화 효과와 유사하게 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다. As can be seen from the results in Table 6, the compound of Chemical Formula 1 had a lower IC 50 value than when vitamin C, which is generally known as an antioxidant, was applied. Therefore, it was found that the compound of Formula 1 exhibits an excellent antioxidant effect and, similar to the anti-glycation effect, acts as an auxiliary agent in skin whitening, elasticity improvement, wrinkle improvement, and skin moisturization, and thus a synergistic effect can be expected.
Claims (10)
[화학식 1]
A cosmetic composition comprising a compound represented by the following formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
[Formula 1]
The cosmetic composition of claim 1, wherein the cosmetic composition is for skin whitening.
The cosmetic composition of claim 1, wherein the cosmetic composition is for improving skin elasticity or improving wrinkles.
The cosmetic composition of claim 1, wherein the cosmetic composition is for moisturizing skin.
The cosmetic according to any one of claims 1 to 4, wherein the composition reduces the total amount of melanin, promotes collagen synthesis, inhibits elastase activity, inhibits collagenase activity, and has anti-glycation or antioxidant effects. Composition.
The method according to any one of claims 1 to 4, wherein the composition is a solution, external ointment, cream, foam, nourishing lotion, softening lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid cleanser, bath agent, Formulations selected from the group consisting of sunscreen creams, sun oils, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays. A cosmetic composition characterized by having a.
상기 식품 조성물은 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 또는 피부 보습용인 것인, 식품 조성물.
[화학식 1]
A food composition containing a compound represented by the following formula (1) or a foodologically acceptable salt thereof as an active ingredient,
The food composition is for skin whitening, improving skin elasticity or wrinkles, or moisturizing the skin.
[Formula 1]
상기 의약외품 조성물은 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 또는 피부 보습용인 것인, 의약외품 조성물.
[화학식 1]
A quasi-drug composition containing a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient,
The quasi-drug composition is for skin whitening, improving skin elasticity or wrinkles, or moisturizing the skin.
[Formula 1]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160083708A KR102601551B1 (en) | 2016-07-01 | 2016-07-01 | Composition for skin improvement containing liriopesides B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160083708A KR102601551B1 (en) | 2016-07-01 | 2016-07-01 | Composition for skin improvement containing liriopesides B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180003920A KR20180003920A (en) | 2018-01-10 |
| KR102601551B1 true KR102601551B1 (en) | 2023-11-13 |
Family
ID=60998385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160083708A KR102601551B1 (en) | 2016-07-01 | 2016-07-01 | Composition for skin improvement containing liriopesides B |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102601551B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100782600B1 (en) | 2006-09-12 | 2007-12-06 | 바이오스펙트럼 주식회사 | Cosmetic compositions for anti-aging of skin comprising diosgenin and dioscin |
| KR100982806B1 (en) | 2010-04-09 | 2010-09-16 | 주식회사 에스앤텍 | The manufacturing method of natural antifungal material for food from dioscoreaceae |
| CN103265609A (en) * | 2013-05-22 | 2013-08-28 | 南京泽朗医药科技有限公司 | Method for preparing liriopesides B |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08133950A (en) * | 1994-11-07 | 1996-05-28 | Shiseido Co Ltd | Skin preparation for external use |
| KR20100093223A (en) * | 2009-02-16 | 2010-08-25 | (주)더페이스샵 | Cosmetic composition containing an extract of ophiopogon japonicus for skin miosture |
| KR101220494B1 (en) | 2010-10-11 | 2013-01-10 | 강원대학교산학협력단 | Cosmetic Composition for Skin Whitening Comprising Liriope Seed Extracts |
| KR101367423B1 (en) * | 2011-12-29 | 2014-02-28 | 원광대학교산학협력단 | Pharmaceutical composition and cosmetic compostion for improving skin condition and preparation method thereof |
-
2016
- 2016-07-01 KR KR1020160083708A patent/KR102601551B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100782600B1 (en) | 2006-09-12 | 2007-12-06 | 바이오스펙트럼 주식회사 | Cosmetic compositions for anti-aging of skin comprising diosgenin and dioscin |
| KR100982806B1 (en) | 2010-04-09 | 2010-09-16 | 주식회사 에스앤텍 | The manufacturing method of natural antifungal material for food from dioscoreaceae |
| CN103265609A (en) * | 2013-05-22 | 2013-08-28 | 南京泽朗医药科技有限公司 | Method for preparing liriopesides B |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180003920A (en) | 2018-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180061664A (en) | Composition for skin improvement containing demethylzeylasteral | |
| KR102425559B1 (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
| KR102629000B1 (en) | Composition for skin improvement containing Salvianolic acid C | |
| KR102639155B1 (en) | Composition for skin improvement containing valechlorine | |
| KR102539619B1 (en) | Composition for improving skin conditions comprising Praeruptorin A | |
| KR102629001B1 (en) | Composition for skin improvement containing diosbulbin B | |
| KR102601551B1 (en) | Composition for skin improvement containing liriopesides B | |
| KR102503190B1 (en) | Composition for improving skin conditions comprising Ajugol | |
| KR102503107B1 (en) | Composition for improving skin conditions comprising Polygalasaponin F | |
| KR102649736B1 (en) | Composition for skin improvement containing brucine | |
| KR102611917B1 (en) | Composition for skin improvement containing Aristolactam I | |
| KR102662257B1 (en) | Composition for skin improvement containing rebaudioside C | |
| KR20180042706A (en) | Composition for skin improvement containing tussilagone | |
| KR102662256B1 (en) | Composition for skin improvement containing Syringaresnol-4-O-β-D-apiofuranosy | |
| KR102636983B1 (en) | Composition for skin improvement containing isodemethylwedelolactone | |
| KR102644106B1 (en) | Composition for skin improvement containing corytuberine | |
| KR102644107B1 (en) | Composition for skin improvement containing vomicine | |
| KR102628373B1 (en) | Composition for skin improvement containing dracorhodin perochlorate | |
| KR102512773B1 (en) | Composition for improving skin conditions comprising bavachinin A | |
| KR102503108B1 (en) | Composition for improving skin conditions comprising Timosaponin A-Ⅲ | |
| KR102503188B1 (en) | Composition for improving skin conditions comprising Gaultherin | |
| KR102523361B1 (en) | Composition for improving skin conditions comprising Dihydrotanshinone I | |
| KR102523896B1 (en) | Composition for improving skin conditions comprising Obacunone | |
| KR102503109B1 (en) | Composition for improving skin conditions comprising Specnuezhenide | |
| KR102523360B1 (en) | Composition for improving skin conditions comprising schisantherin A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |